Chapter 11. A Mechanistic View of Troglitazone Hepatotoxicity

  1. Saura C. Sahu
  1. Rawiwan Maniratanachote and
  2. Tsuyoshi Yokoi

Published Online: 27 FEB 2008

DOI: 10.1002/9780470516751.ch11



How to Cite

Maniratanachote, R. and Yokoi, T. (2007) A Mechanistic View of Troglitazone Hepatotoxicity, in Hepatotoxicity (ed S. C. Sahu), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470516751.ch11

Editor Information

  1. Division of Toxicology, Office of Toxicology, Office of Applied Research and Safety Assessment, Center for Food Safety and Applied Nutrition, US Food and Drug Administration, 8301 Muirkirk Road, Laurel, MD 20708, USA

Author Information

  1. Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Sciences, Kanazawa University, Kakumamachi, Kanazawa 920-1192, Japan

Publication History

  1. Published Online: 27 FEB 2008
  2. Published Print: 14 DEC 2007

ISBN Information

Print ISBN: 9780470057162

Online ISBN: 9780470516751



  • peroxisome proliferator-activated receptor γ (PPAR γ);
  • thiazolidinedione antidiabetic agent;
  • hepatic glucose production;
  • metabolic impairment animal models;
  • idiosyncratic drug reaction;
  • conventional animal models;
  • primate model;
  • rosiglitazone and pioglitazone;
  • clinical dosage regimen;
  • antioxidant property


This chapter contains sections titled:

  • Introduction

  • Potential of Troglitazone Metabolites for Hepatotoxicity

  • Susceptible Genetic Factors Associated with Troglitazone Hepatotoxicity

  • Implications of Canalicular Bile Salt Export Pump and Drug Transporters

  • Hypersensitivity Reaction in Troglitazone Hepatotoxicity

  • Molecular Mechanism of Troglitazone-Induced Liver Toxicity

  • Effect of Troglitazone on the Inhibition of Protein Translation

  • Conclusions and Perspectives

  • Acknowledgments

  • References